Krystal Biotech (KRYS) Projected to Post Quarterly Earnings on Monday

Krystal Biotech (KRYS) is anticipated to report Q3 2025 earnings, with analysts forecasting $1.04 EPS and $93.723 million in revenue, following a strong prior quarter where the company surpassed estimates with $1.29 EPS and $96.04 million in revenue. The commercial-stage biotechnology firm, which specializes in genetic medicines for rare diseases, saw its stock open up 4.5% at $197.51, underpinned by a 'Moderate Buy' consensus rating and recent price target increases from multiple analysts, signaling positive market sentiment.

Analysis

Krystal Biotech (KRYS) is scheduled to release its Q3 2025 earnings on November 3rd, with analysts forecasting $1.04 EPS and $93.723 million in revenue. This follows a robust Q2 2025 performance where the company significantly surpassed estimates, reporting $1.29 EPS against a $1.08 consensus and $96.04 million in revenue, exceeding the $95.42 million forecast. The prior quarter also highlighted strong fundamentals with a 40.85% net margin and 15.21% return on equity.

Analyst sentiment for KRYS remains highly positive, evidenced by a "Moderate Buy" consensus rating and an average price target of $223.00. Several firms recently upgraded their price targets, including Bank of America raising its target from $182.00 to $255.00 and Guggenheim setting a $224.00 target, both maintaining "buy" ratings. The stock itself opened up 4.5% at $197.51, trading above its 50-day ($169.37) and 200-day ($152.91) moving averages, indicating positive market momentum.

The company's P/E ratio of 40.14 reflects high growth expectations, with analysts projecting EPS to grow from $6 for the current fiscal year to $10 for the next. As a commercial-stage biotechnology firm focused on genetic medicines for rare diseases, particularly with its commercialized product VYJUVEK, Krystal Biotech's $5.72 billion market capitalization and a beta of 0.64 suggest a growth-oriented profile with relatively lower market volatility.

Key Decisions for Investors

• Monitor Krystal Biotech's Q3 2025 earnings report closely for confirmation of continued operational strength and alignment with analyst expectations, particularly regarding revenue and EPS figures.
• Evaluate the company's forward guidance for future quarters and fiscal years, as current analyst projections for significant EPS growth from $6 to $10 suggest a strong long-term outlook.
• Consider the strong analyst consensus and recent price target increases as indicators of positive sentiment, but also acknowledge the relatively high P/E ratio of 40.14 which prices in substantial future growth.